Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 16/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7521965 | 0.95 | PTGIR (0.40) | PTGIRPTGDRMEN1POLBKMT2A | |
| SCHEMBL7523923 | 0.92 | ADORA1 (0.38) | PTGIRMEN1POLBKMT2ATBXA2R | |
| SCHEMBL7525237 | 0.89 | PTGIR (0.41) | PTGIRPTGDRMEN1POLBKMT2A | |
| SCHEMBL7529067 | 0.86 | ADORA1 (0.39) | PTGIRMEN1POLBKMT2ATBXA2R | |
| SCHEMBL7520084 | 0.84 | PTGIR (0.42) | PTGIRPTGDRMEN1POLBKMT2A | |
| SCHEMBL7529042 | 0.83 | PTGIR (0.41) | PTGIRPTGDRMEN1POLBKMT2A | |
| SCHEMBL7514860 | 0.81 | PTGIR (0.42) | PTGIRPTGDRMEN1POLBKMT2A | |
| SCHEMBL7519017 | 0.81 | PTGIR (0.42) | PTGIRPTGDRMEN1POLBKMT2A | |
| SCHEMBL7527902 | 0.81 | PTGIR (0.39) | PTGIRPTGDRPTGDR2 | |
| SCHEMBL7528910 | 0.80 | PTGIR (0.39) | PTGIRPTGDRPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417213-B2 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| US-20020006944-A1 | Tricyclic compounds, their production and use | OHKAWA SHIGENORI (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6248766-B1 | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006944-A1 | Tricyclic compounds, their production and use | CNR1, PTGER1, PTGDR | PTGIR 11/4885PTGDR 3/4885MEN1 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.